Are people biologically prepared for the rapid detection of threat posed by an angry facial expression, even when it is conveyed in the form of a schematic line drawing? Based on visual search times, the current literature would suggest that the answer is yes. But are there lowlevel explanations for this effect? Here, we present visual search results for schematic faces using current best practice, based on a concentric search array and set size manipulation. Using this approach, we replicate the classic search advantage for angry over happy faces. However, we also report a comparable effect when abstract plus-and square-shaped stimuli-derived from the angry and happy schematic faces respectively-are used within the same paradigm. We then go on to demonstrate that, while reduced, the effect remains after removal of the circular surround, bringing us closer to the source of the effect. We explore the possibility that the source of this search asymmetry could be the iso-feature suppression and collinear facilitation model proposed in Li's (1999a, 1999b, and 2002) bottom-up model of saliency. Simulations with this model using the abstract stimuli align with the corresponding behavioral results (i.e., the plus shape was found to be more salient than the square). Given the deliberate similarities between these abstract shapes and the respective face stimuli, we propose that the underlying cause for the asymmetries typically found using schematic faces, may be more related to early visual processing of line orientation than threat detection.

Background: Wixela Inhub (trademarks of Viatris, Inc.) is a dry powder inhaler (DPI) that delivers a fixed-dose combination of fluticasone propionate and salmeterol and is approved as a generic equivalent to Advair Diskus (trademarks of GlaxoSmithKline plc) for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The dosing performance of DPIs is dependent on the patient's inspiratory capability, which may be impacted in disease populations such as those with severe COPD. The objective of this study was to evaluate the in vitro dose delivery of fluticasone propionate and salmeterol from the Inhub inhaler with in vivo inhalation profiles of severe COPD patients, using two types of breathing simulator with different modes of operation. Materials and Methods: Two breathing simulators (Si-Plan and Copley BRS3100) were used with United States Pharmacopoeia (USP) <601> apparatus 5 (Next Generation Impactor and accessories) to measure the total emitted dose and fine particle mass of fluticasone propionate and salmeterol for Wixela Inhub (250/50 mcg) using 13 severe COPD patient inhalation profiles. Results: Wixela Inhub demonstrated low flow dependency across the range of COPD patient profiles tested (peak inspiratory flow rate 60.8–84.9 L minute −1 ), when assessed by total emitted dose and fine particle mass. The results were similar to literature results reported for fluticasone propionate from the Diskus inhaler, tested using a proprietary breathing simulator and Andersen Cascade Impactor. Comparison between the breathing simulators showed no significant difference in fluticasone propionate results, but a small difference was observed between the breathing simulators for salmeterol total emitted dose and fine particle mass. Conclusions: This study demonstrates that severe COPD patients are likely to achieve a consistent inhaled dose from Wixela Inhub, with low flow dependency observed within this patient population. In addition, both breathing simulators, which differ significantly in design, produced similar results for fluticasone propionate, but yielded slightly (but statistically significant) different results for salmeterol.